Taurine clinical brief
Taurine
Dossier liveBCardiovascular
Evidence strength
High confidence
24 meta-analyses - 192 RCTs - 386 tracked studies
What it is for
Type 2 diabetes mellitus and metabolic syndrome - glycemic, lipid, and inflammatory biomarker improvement
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HOMA-IR
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
Decrease
Grade A
Fasting glucose
Glycemic control
Decrease
Grade A
Top caution
Insulin and insulin secretagogues (sulfonylureas, glinides)
Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day
Evidence index
71
Authored product-registry confidence score
Meta-analyses
24
Pooled human evidence
RCTs
192
Randomized clinical trials
Tracked studies
386
Studies currently mapped to this dossier
Executive summary
Immediate brief
Taurine is a Cardiovascular with its clearest current use in Type 2 diabetes mellitus and metabolic syndrome - glycemic, lipid, and inflammatory biomarker improvement.
High confidence human evidence supports the brief, anchored by 386 tracked studies, 24 meta-analyses, 192 RCTs and the most reliable movement in HOMA-IR, HbA1c, Fasting glucose.
Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day Clinically meaningful in T2DM patients on insulin or sulfonylureas; additive glucose lowering could cause symptomatic hypoglycemia at taurine doses >=2 g/day
Anchor decision
Type 2 diabetes mellitus and metabolic syndrome - glycemic, lipid, and inflammatory biomarker improvement
Best current human use case
Confidence
High confidence
24 meta-analyses - 192 RCTs - 386 tracked studies
Read next
Insulin and insulin secretagogues (sulfonylureas, glinides)
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
DPregnancy - supplemental doses >500 mg/day above dietary baseline
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Evidence scope
ReviewTaurine is an essential dietary amino acid in cats, who lack adequate cysteine sulfinic acid decarboxylase (CSAD) activity to synthesize taurine de novo and obligately conjugate bile acids with taurine (not glycine).
Evidence scope
ReviewMost adverse event reports attributed to 'taurine' in energy drink contexts involve co-administration with high-dose caffeine (80-300 mg per can), glucuronolactone, B-vitamins, and sugar.
Generalizability
ReviewThe majority of cardiovascular RCT-level evidence for taurine derives from Japanese populations: Azuma et al.
Missing populations
CoverageNeeds replication in European, African American, Hispanic/Latino, South Asian.
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
Taurine + caffeine
CANONICAL ENTRY.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.